Tiziana Life Sciences Ltd
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ivor R. Elrifi
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 55 Park Lane London United Kingdom W1K 1NA
- IPO Date
- Nov 20, 2018
- CIK
- 0001723069
- Website
- tizianalifesciences.com
- Similar Companies
- Business
- Tiziana Life Sciences Ltd (Nasdaq: TLSA), a clinical-stage biotechnology company headquartered in London, United Kingdom and founded in 1998, develops breakthrough immunomodulation therapies via innovative nasal delivery technologies for neurodegenerative, neuroinflammatory and autoimmune diseases; its lead candidate is intranasal Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody in Phase 2a trials for non-active secondary progressive multiple sclerosis (na-SPMS; dosing began 4Q 2023), multiple system atrophy (MSA; dosing began August 2025), amyotrophic lateral sclerosis (ALS; Phase 2 to begin 2H 2025 with ALS Association grant), mild Alzheimer's disease (Phase 2 to begin 2H 2025) and moderate Alzheimer's (expanded access dosing began December 2024), with investigational new drug application planned for long COVID and preclinical exploration in early onset type 1 diabetes mellitus and intracerebral hemorrhage; it also advances TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting inflammatory and oncology indications including lung diseases via dual inhibition of membrane-bound and soluble IL-6R, and evaluates milciclib in combination with gemcitabine for KRAS-positive non-small cell lung cancer; prior formulations of Foralumab include well-tolerated oral and intravenous routes tested in Phase 1/2 for Crohn's disease. In recent developments, Tiziana announced in December 2025 plans to spin out TZLS-501 and related assets into a separate publicly listed immunology-focused company to unlock value and sharpen strategic focus amid heightened IL-6 pathway interest following Novartis' $1.4 billion acquisition of Tourmaline Bio, subject to shareholder approval; CEO Ivor Elrifi purchased 193,848 common shares at $1.65 each in September 2025 signaling management confidence; the company secured a U.S. Department of Defense grant in September 2025 to accelerate intranasal Foralumab and its expanded access program for na-SPMS dosed 14 patients with observed stability or improvement; Executive Chairman Gabriele Cerrone increased insider ownership to 36.28% through recent purchases. Tiziana operates globally with clinical trials across multiple sites, supported by extensive patents through 2040 on compositions, formulations and indications, and maintains a lean team of nine employees focused on alternative immunotherapy routes to enhance efficacy, safety and tolerability over intravenous delivery.
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference
FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Dow Jones pokes ahead after IBM's quantum injection, Nvidia earnings
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Tiziana Life Sciences price target boosted on foralumab update
MongoDB price target lifted by Bank of America ahead of earnings on execution confidence, Atlas momentum
Tiziana Life Sciences price target boosted on foralumab update
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
S&P and Nasdaq close at record highs on ceasefire optimism and tech strength
Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function